Muscle sympathetic nerve activity in COPD: a systematic review and meta-analysis
Open Access
- 1 April 2026
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 35 (180) , 250267
Abstract
Background: Cardiovascular disease is a primary driver of mortality in COPD. Elevated sympathetic nerve activity is a key proposed mechanism, but the magnitude of this autonomic overactivity has not been quantified in a pooled analysis. Objective: To determine if adults with COPD exhibit higher resting muscle sympathetic nerve activity (MSNA) than healthy controls, assess associated cardiorespiratory effects, and evaluate the short-term impact of COPD interventions on MSNA. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, eight databases were searched from inception to 15 May 2025 to inform this systematic review and meta-analysis (PROSPERO CRD420251044931). Eligible studies included adults with spirometry-defined COPD in whom MSNA was measured by microneurography at rest. Primary outcomes were MSNA burst frequency (bursts·min −1 ) and incidence (bursts per 100 heartbeats). Secondary outcomes included resting heart rate and blood pressure. Results: A total of 11 studies (171 COPD participants, 105 controls) met inclusion criteria. Compared with controls, COPD was associated with markedly higher MSNA, burst frequency (+18.5, 95% CI 9.4–27.7 bursts·min −1 ) and burst incidence (+21.3, 95% CI 9.2–33.4 bursts per 100 heartbeats). Resting heart rate was also elevated (+10.7, 95% CI 6.1–15.3 beats·min −1 ), while blood pressure did not differ significantly. Three studies on noninvasive ventilation or inhaled β 2 -agonists found no significant pooled changes in MSNA. Conclusions: Resting MSNA is significantly elevated in patients with COPD despite normal blood pressure. This chronic sympathetic excitation likely contributes to COPD-related cardiovascular morbidity and exercise intolerance, highlighting the importance of developing therapies that reduce sympathetic nerve activity.Keywords
This publication has 34 references indexed in Scilit:
- Cardiovascular disease and risk in COPD: a state of the art reviewExpert Review of Cardiovascular Therapy, 2024
- Effective non-invasive ventilation reduces muscle sympathetic nerve activity in patients with stable hypercapnic COPDClinical Autonomic Research, 2024
- Sympathetic vascular transduction and baroreflex sensitivity in the context of severe COPDClinical Autonomic Research, 2023
- COPD and Cardiovascular DiseasePulmonology, 2019
- The carotid chemoreceptor contributes to the elevated arterial stiffness and vasoconstrictor outflow in chronic obstructive pulmonary diseaseThe Journal of Physiology, 2018
- Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015The Lancet Respiratory Medicine, 2017
- Impact of Non-Invasive Ventilation on Sympathetic Nerve Activity in Chronic Obstructive Pulmonary DiseaseLung, 2016
- Increased Sympathetic Nerve Activity in COPD is Associated with Morbidity and MortalityLung, 2013
- Sympathetic Nerve Activity Is Inappropriately Increased in Chronic Renal DiseaseJournal of the American Society of Nephrology, 2003
- Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2000